Related Experiment Videos
G-CSF-primed peripheral blood progenitor cells (PBPC) support in high-risk Ewing sarcoma of childhood
Insights
Pediatric high-risk Ewing sarcoma patients received high-dose chemotherapy with stem cell support. This pilot study evaluated treatment toxicity, hospitalization, and bone marrow recovery after this intensive therapy.
Area of Science:
- Pediatric Oncology
- Hematology
- Cancer Therapeutics
Background:
- High-risk Ewing sarcoma in pediatric patients often presents with large pelvic masses or metastatic disease.
- Established treatment protocols are crucial for improving outcomes in these challenging cases.
Purpose of the Study:
- To evaluate the safety and efficacy of high-dose chemotherapy with stem cell support in pediatric patients with high-risk Ewing sarcoma.
- To assess treatment-related toxicity, hospitalization duration, and bone marrow function recovery.
Main Methods:
- A pilot study enrolled 17 pediatric patients with high-risk Ewing sarcoma.
- Patients underwent high-dose chemotherapy (HDCT) followed by peripheral blood progenitor cell transplantation (PBPCT) with G-CSF priming.
Main Results:
- The study assessed treatment-related toxicity, hospitalization periods, and bone marrow function rescue.
- Detailed outcomes regarding these parameters were analyzed for the 17 enrolled patients.
Conclusions:
- High-dose chemotherapy with stem cell support is a consolidative strategy for high-risk pediatric Ewing sarcoma.
- Further analysis is needed to fully understand the toxicity profile and bone marrow recovery post-HDCT and PBPCT.
Abstract:
Since 1993 pediatric patients affected by high-risk Ewing sarcoma for the presence at onset of a large pelvic mass and/or metastatic disease, were enrolled in a national pilot study comprehensive, finally, of a high-dose chemotherapy (HDCT) procedure with hemopoietic stem cell support. The HDCT procedure considered as consolidation of the disease status obtained after the first-line therapy was followed by the reinfusion of granulokine colony-stimulating factor-primed (G-CSF) peripheral blood progenitor cell (PBPCT). Here we present the results in terms of treatment-related toxicity, hospitalization and rescue of the bone marrow function, in 17 pediatric patients enrolled in such a pilot protocol and submitted to HDCT and PBPCT at the end of first-line therapy.